Core Viewpoint - The stock of Insilico Medicine (3696.HK) surged by 17% to a new high of HKD 55, marking a cumulative increase of over 52% since its listing, with a market capitalization exceeding HKD 30 billion, following a significant R&D collaboration announcement with Servier worth USD 888 million focused on oncology drug development [1] Group 1: Company Developments - Insilico Medicine announced a research collaboration with Servier totaling USD 888 million, aimed at identifying and developing new therapeutic drugs for challenging oncology targets [1] - The company has established numerous AI-driven drug development collaborations and pipeline licensing agreements in recent years [1] Group 2: Market Context - The rise in Insilico Medicine's stock price is attributed to multiple factors, including recent advancements in the AI healthcare sector and collaborations by other AI pharmaceutical companies, such as CrystalGenomics [1] - The AI medical industry is experiencing significant progress, with new catalysts emerging in areas like brain-computer interfaces and innovative drug development [1]

Group 1 - The core viewpoint of the article highlights the significant stock price increase of Insilico Medicine (3696.HK), which surged by 17% to reach a new high of 55 HKD, marking a cumulative increase of over 52% since its listing, with a market capitalization exceeding 30 billion HKD [1] - Insilico Medicine recently announced a research collaboration with Sivea, valued at 888 million USD, focusing on challenging targets in the oncology field to identify and develop new therapeutic drugs [1] - The stock price increase is attributed to multiple factors, including recent advancements in the AI healthcare industry, with Insilico's collaboration with Sivea and other strategic partnerships, such as the one with JinkoSolar's subsidiary by another AI pharmaceutical company, highlighting a trend of innovation in the sector [1]

Core Viewpoint - The stock of Insilico Medicine (03696) surged nearly 15% in early trading, reaching a high of HKD 54, which represents an increase of over 124% from its IPO price of HKD 24.05 [1] Group 1: Clinical Development - Insilico Medicine announced the completion of the first dosing of its innovative PHD inhibitor ISM5411 in a Phase IIa clinical trial named BETHESDA [1] - The candidate drug, developed with the company's proprietary generative AI platform Pharma.AI, is designed for the treatment of inflammatory bowel disease (IBD) and has recently received official approval for its generic name Garutadustat from the USAN Council [1] Group 2: Strategic Partnerships - On January 5, Insilico Medicine announced a multi-year collaboration with Sihuan Pharmaceutical for the development of anti-tumor drugs, with a total collaboration amount of USD 888 million [1] - Insilico Medicine is eligible to receive up to USD 32 million in upfront payments and milestone payments for recent research developments [1] - The company will utilize its self-developed AI platform Pharma.AI to focus on challenging targets in the anti-tumor field, identifying and developing new therapeutic drugs, while Sihuan will share the research costs and lead subsequent clinical validation and commercialization processes [1]

Core Viewpoint - The stock of Insilico Medicine (03696) surged nearly 15% in early trading, reaching a high of 54 HKD, which represents an increase of over 124% from its IPO price of 24.05 HKD [1] Group 1: Clinical Trials and Drug Development - Insilico Medicine announced the completion of the first dosing of its innovative PHD inhibitor ISM5411 in a Phase IIa clinical trial named BETHESDA [1] - The candidate drug, developed with the company's proprietary generative AI platform Pharma.AI, is designed for the treatment of inflammatory bowel disease (IBD) and has recently received official approval for its generic name Garutadustat from the USAN Council [1] Group 2: Strategic Partnerships - On January 5, Insilico Medicine announced a long-term collaboration with SIVAN to develop anti-tumor drugs, with a total collaboration amount of 888 million USD [1] - Insilico Medicine is eligible to receive up to 32 million USD in upfront payments and milestone payments for recent research developments [1] - The company will utilize its self-developed AI platform Pharma.AI to focus on challenging targets in the anti-tumor field, identifying and developing new therapeutic drugs, while SIVAN will co-share the research costs and lead subsequent clinical validation and commercialization processes [1]

Core Insights - The company has completed the first dosing of its innovative PHD inhibitor ISM5411 in a Phase IIa clinical trial named BETHESDA, which focuses on treating inflammatory bowel disease (IBD) [1] - The company has entered into a licensing collaboration with TaiJing for another innovative candidate drug ISM4808, aimed at treating anemia related to chronic kidney disease (CKD), with a total collaboration value of tens of millions of dollars [2] Group 1 - The innovative candidate drug ISM5411, developed with the assistance of the company's proprietary AI platform Pharma.AI, has received the official generic name Garutadustat from the USAN Council [1] - The ongoing multi-center, randomized, double-blind, placebo-controlled Phase IIa clinical study will evaluate the clinical application potential of Garutadustat in approximately 80 patients with ulcerative colitis (UC), focusing on safety, tolerability, and pharmacokinetic (PK) characteristics [1] - The study will explore efficacy signals through various multidimensional indicators, including clinical remission/response, endoscopic examination, histopathology, and biomarkers [1] Group 2 - The collaboration with TaiJing aims to leverage clinical and market expertise alongside the company's AI-driven drug development efficiency to address unmet medical needs [2] - The integration of advanced AI and automation technologies has significantly enhanced early-stage new drug development efficiency, setting a benchmark for AI-driven drug development [2] - Compared to the traditional drug development cycle of approximately 4.5 years, the company's self-research projects from 2021 to 2024 have an average timeline of only 12-18 months from project initiation to PCC nomination, requiring the synthesis and testing of about 60-200 molecules per project [2]

Core Insights - The company, Yingkui Intelligent (03696), has completed the first dosing of its innovative PHD inhibitor ISM5411 in a Phase IIa clinical trial named BETHESDA, aimed at treating inflammatory bowel disease (IBD) [1] - The generic name Garutadustat for ISM5411 has been officially approved by the USAN Council, indicating regulatory progress for the drug [1] - The ongoing multi-center, randomized, double-blind, placebo-controlled Phase IIa study will evaluate the clinical application potential of Garutadustat in approximately 80 patients with ulcerative colitis (UC), focusing on safety, tolerability, pharmacokinetics (PK), and efficacy signals through various multidimensional indicators [1] Company Developments - Yingkui Intelligent has entered into an external licensing collaboration with Taijing for another innovative candidate drug ISM4808, aimed at treating anemia related to chronic kidney disease (CKD), with a total collaboration value of tens of millions of dollars [2] - The collaboration aims to leverage Taijing's clinical and market expertise alongside Yingkui Intelligent's AI-driven drug development efficiency to address unmet medical needs [2] - The company has significantly enhanced early-stage new drug development efficiency through the integration of advanced AI and automation technologies, setting a benchmark for AI-driven drug development [2] - Compared to the traditional drug development cycle of approximately 4.5 years, Yingkui Intelligent's self-research projects from 2021 to 2024 have an average timeline of only 12-18 months from project initiation to PCC nomination, requiring the synthesis and testing of about 60-200 molecules per project [2]

Core Viewpoint - The company, 英矽智能 (03696.HK), has initiated the first dosing of its innovative PHD inhibitor ISM5411 in a Phase IIa clinical trial named BETHESDA, aimed at treating inflammatory bowel disease (IBD) [1] Group 1: Clinical Trial Details - The BETHESDA trial is a multi-center, randomized, double-blind, placebo-controlled study [1] - The trial is led by Professor Chen Minhu, a prominent expert in gastroenterology from Sun Yat-sen University First Affiliated Hospital [1] - Approximately 80 patients with ulcerative colitis (UC) will be evaluated for the clinical application potential of Garutadustat (formerly ISM5411) [1] Group 2: Drug Development and Approval - Garutadustat has recently received official approval from the USAN Council for its generic name [1] - The drug is developed using the company's proprietary generative AI platform, Pharma.AI, and is characterized by its intestinal restriction [1] Group 3: Evaluation Metrics - The trial will assess safety, tolerability, and pharmacokinetic (PK) characteristics of Garutadustat [1] - Effectiveness signals will be explored through multiple indicators, including clinical remission/response, endoscopic examination, histopathology, and biomarkers [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 於本公告日期，本公司董事會包括執行董事Aleksandrs Zavoronkovs博士及任峰博 士，非執行董事陳侃博士、梁傳昕博士及施瓏先生，以及獨立非執行董事王勁松 博士、Denitsa Milanova博士及Roman Kyrychynskyi先生。 INSILICO MEDICINE InSilico Medicine Cayman TopCo 英矽智能 （於開曼群島註冊成立的有限公司） （股份代號：3696） 有關在名為BETHESDA的IIA期臨床試驗中完成 GARUTADUSTAT (ISM5411)首例受試者給藥之自願公告 本公告乃由英矽智能（「本公司」，連同其附屬公司統稱「本集團」）自願作出。 本公司謹此知會本公司股東及潛在投資者，隨附之新聞稿載述，本公司已在一項 名為BETHESDA的IIa期臨床試驗中完成其創新PHD抑制劑ISM5411的首例受試者 給藥。該創新候選藥物由本集團自有生成 ...

Summary of Key Points Core Viewpoint - As of January 9, a total of 73 stocks reached their 52-week highs, with notable performances from Lingxiong Technology (02436), Delai Construction (01546), and Zhipu (02513) showing significant growth rates of 104.99%, 38.89%, and 22.22% respectively [1]. 52-Week Highs - Lingxiong Technology (02436) closed at 11.760, with a peak price of 15.600, achieving a high rate of 104.99% [1]. - Delai Construction (01546) closed at 0.161, reaching a maximum of 0.250, with a high rate of 38.89% [1]. - Zhipu (02513) had a closing price of 158.600 and a peak of 165.000, resulting in a high rate of 22.22% [1]. - Other notable stocks include Asia Pacific Satellite (01045) with a high rate of 20.64% and Rongda Technology (09881) at 12.87% [1]. 52-Week Lows - The stocks reaching their 52-week lows include Lishi International (00842) with a closing price of 0.850, marking a decline of 39.29% [2]. - Bokan Vision Cloud - B (02592) closed at 2.930, with a decrease of 16.90% [2]. - Lingzai Technology Finance (00093) reached a low of 0.485, reflecting a drop of 14.77% [2].

在微软的支持及Microsoft Foundry的技术加持下，英矽智能近日对DORA进行了重要功能升级。升级后 的DORA可与多种Foundry模型无缝集成，包括顶级的O3 Deep Research模型，从而显著提升科研内容创 作效率与输出质量。 除DORA社区版外，英矽智能还为有更高阶、专业化需求的用户提供更为全面的DORA SaaS版本。与开 源版本相比，DORA SaaS可访问英矽智能靶点发现引擎 PandaOmics中预先分析的"蛋白–疾病关联"报 告，从而获得更深入的领域专属洞察；同时，其接入英矽智能数据仓库，支持即时文内引文。 英矽智能(03696)涨近5%，盘中高见42.66港元创上市新高。截至发稿，涨4.94%，报42.5港元，成交额 7646.48万港元。 消息面上，1月8日，英矽智能宣布，公司推出DORA社区版(DORA Community Edition)——一款面向科 学研究与内容创作的免费且可自主部署版本的综合性AI引擎。DORA社区版由英矽智能发起、并在微软 支持下推出，旨在让更多人能够使用最前沿的科研工具，推动全球科研协作，提升科学研究的透明度， 加速生物技术及学术界的创新进程 ...